Consensus document 2006 of the Spanish Society of Rheumatology about postmenopausal osteoporosis;Documento de Consenso 2006 de la Sociedad Española de Reumatología sobre la osteoporosis posmenopáusica

Reumatologia Clinica

Volumn 3, Issue EXTRA.1, 2007, Pages 26-32

  Escofet, Daniel Roig ^a   Edo, Lluís Pérez ^a   Ruiz, Alberto Alonso ^a   Rodríguez, Luis Arboleya ^a   Audera, Jesús Beltrán ^a   Rubió, Josep Blanch ^a   Freire, Manuel Caamaño ^a   Abelló, Jordi Carbonell ^a   Aresté, Jordi Fiter ^a   Vadillo, J Alberto García ^a   Gil, Jenaro Graña ^a   Gay, Núria Guañabens ^a   Montes, Javier Del Pino ^a   Pérez, Manuel Rodríguez ^a   Vilaseca, Daniel Roig ^a   Heredia, Esteban Salas ^a   Eslava, Antonio Torrijos ^a   Tabernero, Jaime Zubieta ^a   Villar, María Alcalde ^a   Pérez, Susana Holgado ^a   Santamaría, Estíbaliz Loza ^a   more..

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCITONIN; ESTROGEN; ETIDRONIC ACID; IBANDRONIC ACID; PARATHYROID HORMONE; PARATHYROID HORMONE DERIVATIVE; PARATHYROID HORMONE[1-34]; RALOXIFENE; RISEDRONIC ACID; SELECTIVE ESTROGEN RECEPTOR MODULATOR; STRONTIUM RANELATE;

ADULT; BONE DENSITY; COMBINATION CHEMOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; CONFERENCE PAPER; CONSENSUS; DOSAGE SCHEDULE COMPARISON; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; HUMAN; MEDICAL SOCIETY; POSTMENOPAUSE OSTEOPOROSIS; SPAIN; TREATMENT INDICATION;

EID: 44949169467     PISSN: 1699258X     EISSN: 18851398     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (37)

1. Beral V. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet. 2003;362:419-27.
2. Bischoff-Ferrari HA, Willet WC, Wong JB, Giovannuci E, Dietrich T, Dawson-Hughes B. Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials. JAMA. 2005;293:2257-64.
3. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-41.
4. Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, Lang TF, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349:1207-15.
5. Boonen S, Nijs J, Borghs H, Peeters H, Vanderschueren D, Luyten FP. Identifying postmenopausal women with osteoporosis by calcaneal ultrasound, metacarpal digital X-ray radiogrametry and phalangeal radiographic absorptiometry: a comparative study. Osteoporosis Int. 2005;16:93-100.
6. Bone HG, Hosking D, Devogelaer JP, Tucci JR, Emkey RD, Tonino RP, et al. Ten years' experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med. 2004; 350:1189-99.
7. Cosman F, Nieves J, Woelfert L, Formica C, Gordon S, Shen V, et al. Parathyroid hormone added to established hormone therapy: effects on vertebral fractures and maintenance of bone mass after parathyroid hormone withdrawal. J Bone Miner Res. 2001;16:925-31.
8. Chapuy MC, Arlot M, Duboeuf F, Brun J, Crouzet B, Arnaud S, et al. Vitamin D3 and calcium to prevent hip fractures in elderly women. N Engl J Med. 1992;327:1637-42.
9. Chesnut CH, Silverman S, Andriano K, Genant H, Gimona A, Harris S, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteporosis: the Prevent Recurrence of Osteoporotic Fractures Study. Am J Med. 2000;109:267-76.
10. Cranney A, Guyatt G, Griffith L, Wells G, Tugwell P, Rosen C. Osteoporosis Methodology Group and the Osteoporosis Research Advisory Group. Meta-analyses of therapies for postmenopausal osteoporosis. IX. Summary of meta-analyses of therapies for postmenopausal osteoporosis. Endocr Rev. 2002;23:570-8.
11. Diamond TH, Champion B, Clark WA. Management of acute osteoporotic vertebral fractures: a nonrandomized trial comparing percutaneous vertebraplasty with conservative therapy. Am J Med. 2003;114:257-65.
12. Eddy DM, Jonhston CC, Cummings SR, Dawson-Hughes B, Lindsay R, Melton III LJ, et al. Osteoporosis: Review of evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Osteoporos Int. 1998;8 Suppl 4:S1-88.
13. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene. Results from a 3-year randomized clinical trial. JAMA. 1999;282:637-45.
14. Grady D, Herrington D, Bittner V, Blumenthal R, Davidson M, Hlatky M, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:49-57.
15. Greenspan S, Bone HG, Marriott TB, Zanchetta JR, Ettinger MP, Hanley DA, et al. Preventing the first vertebral fracture in postmenopausal women with low bone mass using PTH (1-84): Results from the TOP Study. Nashville: ASBMR 27th Annual Meeting; 2005. p. 1222.
16. Garnero P, Darte C, Delmas PD. A model to monitor the efficacy of alendronate treatment in women with osteoporosis using a biochemical marker of bone turnover. Bone. 1999;24:603-9.
17. Grupo de Trabajo de la Sociedad Española de Investigaciones Óseas y Metabolismo Mineral (SEIOMM). Osteoporosis postmenopá usica. Guía de Práctica Clínica. Rev Clin Esp. 2003;203:496-506.
18. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group. JAMA. 1999;282:1344-52.
19. Hulley S, Furberg C, Barrett-Connor E, Cauley J, Grady D, Haskell W, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and estrogen/progestin replacement study follow-up (HERS II). JAMA. 2002;288:58-66.
20. Marin F, Gonzalez-Macias J, Diez-Pérez A, Palma S, Delgado-Rodriguez M. Relationship betwen bone quantitative ultrasound an fractures a meta-analysis. J Bone Miner Res. 2006;21:1127-35.
21. Martino S, Disch D, Dowsett SA, Keech CA, Mershon JL. Safety assessment of raloxifene over eight years in a clinical trial setting. Curr Med Res Opin. 2005;21:1441-5.
22. Mellstrom DD, Sorensen OH, Goemaere S, Roux C, Johnson TD, Chines AA. Seven years of treatment with risedronate in women with postmenopausal osteoporosis. Calcif Tissue Int. 2004;75:462-8.
23. Meunier Pj, Roux C, Seeman E, Ortalani S, Badurski JE, Spector TD, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med. 2004;350:459-68.
24. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study. J Bone Miner Res. 2005;20:1315-22.
25. Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, et al. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med. 2001;344:1434-41.
26. NIH Consensus conference: Optimal calcium intake. NIH Consensus development panel on optimal calcium intake. JAMA. 1994;272:1942-8.
27. NIH Consensus development panel on osteoporosis: prevention, diagnosis and therapy. JAMA. 2001;285:785-95.
28. Panel de expertos. Documento de la Sociedad Española de Reumatología sobre la osteoporosis posmenopáusica. Rev Esp Reumatol. 2001;28:148-53.
29. Panel de expertos. Documento de Consenso sobre Osteoporosis Postmenopáusica de la Sociedad Española de Reumatología. Rev Esp Reumatol. 2003;30:565-73.
30. Prodigy Guidance. Osteoporosis-treatment and prevention of fragility fracture, 2006. Disponible en: http://www.prodigy.nhs.uk/
31. Pyon EY. Once-monthly ibandronate for postmenopausal osteoporosis: review of a new dosing regimen. Clin Ther. 2006;28:475-90.
32. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ralenate reduce the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of peripheral osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005;90:2816-22.
33. The Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-33.
34. Tornero J, Vidal J, Alonso A, Acebes C, Arboleya L, Calvo J, et al. Documento de Consenso de la Sociedad Española de Reumatología para el uso de opioides en el tratamiento del dolor reumático. Reumatol Clin. 2006;2 Supl 1:50-4.
35. Watts NB. Clinical utility of biochemical markers of bone remodeling. Clin Chem. 1999;45:1359-68.
36. Watts NB, Harris ST, Genant HK, Wasnich RD, Miller PD, Jackson RD, et al. Intermittent cyclical etidronate treatment of postmenopausal osteoporosis. N Engl J Med. 1990;323:73-9.
37. WHO Study Group on assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Technical Report Series 843. Geneva: WHO; 1994.